Press Releases

Here is an up-to-date collection of any information given to the press. It’s a big collection, so try not to look at it all in one sitting.

Press Releases

 
Press Releases
Date Title and Summary View
Jan 19, 2006 NEW YORK, NY - January 19, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today the appointment of Barbara Wallner, Ph.D., as Senior Vice President, Technical Operations and Chief Technical Officer, reporting to Dick Bagley, President and Chief Operating Officer. Dr. Wallner will be located in the Company's Charlestown, MA office and...
PDF
Jan 17, 2006 NEW YORK, NY - January 17, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP), announced today it received a notice of allowance from the U.S. Patent and Trademark Organization in a second organic arsenic case, its first organic arsenic case having already issued. The allowed claims cover the treatment of cancer using organic arsenics, including ZIO...
PDF
Jan 9, 2006 NEW YORK, NY - January 09, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP), announced today the appointment of Robert Morgan, MS, JD, as Vice President of Regulatory Affairs and Quality, and Contract Counsel, reporting to Dick Bagley, President and Chief Operating Officer. He will be located in the Company's operational office in Charlestown, M...
PDF
Jan 6, 2006 NEW YORK, NY - January 06, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today that its company information will be made available via Standard & Poor's Market Access Program, an information distribution service that enables subscribing publicly traded companies to have their company information readily available and disseminated to...
PDF
Jan 4, 2006 NEW YORK, NY - January 4, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP), announced today it received approval from the FDA (U.S. Food and Drug Administration) to initiate a Phase I/II trial with one of its two lead products, ZIO-101, a novel organic arsenic, in patients with advanced myeloma. This announcement follows a similar approval for a...
PDF
Nov 21, 2005 NEW YORK, NY - November 21, 2005 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today the publication of an abstract on ZIO-201, a stabilized form of isophosphoramide mustard (IPM). The preclinical abstract is published and available online in Blood, the official journal of the American Society of Hematology. In abstract 4727 tit...
PDF
Nov 21, 2005 NEW YORK, NY - November 21, 2005 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today the publication of abstracts on its lead product candidate, ZIO-101. The preclinical abstracts are published and available online in Blood, the official journal of the American Society of Hematology. The abstracts include: Abstract 5163:...
PDF
Nov 18, 2005 PHILADELPHIA, PA - November 18, 2005 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today that preclinical data for ZIO-102, an organic arsenic derivative, was presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia, PA. The abstract titled "Mechanisms of increased reactive oxy...
PDF
Nov 16, 2005 PHILADELPHIA, PA - November 16, 2005 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today that ZIO-101, a novel organic arsenic, has demonstrated safety at doses approximately 25 times higher than the currently approved dose for arsenic trioxide, an inorganic arsenic, in an ongoing Phase I trial that has treated 11 patients to date at The...
PDF
Oct 31, 2005 NEW YORK, NY - October 31, 2005 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today that Dr. Jonathan Lewis, Chief Executive Officer, will present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference on Monday, November 7, 2005 at 8:40 a.m. EST at The New York Palace Hotel in New York, NY. Dr. Lewis will provide an overview ...
PDF
Page: FirstPrevious ...
40
NextLast